Appearing as a promising breakthrough in the battle against obesity, this medication is attracting considerable interest . It combines the action of two known GLP-1 receptor agonists, liraglutide, with an additional glucose-dependent incretin component. Preliminary study data have shown significant body reduction in patients with excessive weight,